Immunome, Inc. (IMNM)

NASDAQ: IMNM · IEX Real-Time Price · USD
10.67 -0.38 (-3.44%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap129.11M
Revenue (ttm)n/a
Net Income (ttm)-20.93M
Shares Out12.10M
EPS (ttm)-1.89
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume22,451
Open10.72
Previous Close11.05
Day's Range10.14 - 10.93
52-Week Range10.14 - 63.78
Betan/a
AnalystsStrong Buy
Price Target33.00 (+209.3%)
Earnings DateNov 16, 2021

About IMNM

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

IndustryBiotechnology
IPO DateOct 2, 2020
Employees23
Stock ExchangeNASDAQ
Ticker SymbolIMNM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for Immunome stock is "Strong Buy." The 12-month stock price forecast is 33.00, which is an increase of 209.28% from the latest price.

Price Target
$33.00
(209.28% upside)
Analyst Consensus: Strong Buy

News

FDA Issues Clinical Hold On Immunome's COVID-19 Antibody Program

Immunome Inc (NASDAQ: IMNM) has received an FDA clinical hold letter in response to its recently submitted IND requesting further information related to the preparation and administration of IMM-BCP-01 ...

5 days ago - Benzinga

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today...

6 days ago - Business Wire

Immunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today...

1 month ago - Business Wire

Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, annou...

1 month ago - Business Wire

Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of CO...

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, annou...

1 month ago - Business Wire

Immunome Reports Third Quarter 2021 Financial Results

EXTON, Pa.--(BUSINESS WIRE)--Immunome Reports Third Quarter 2021 Financial Results

2 months ago - Business Wire

Immunome to Present at the Stifel Healthcare Conference

EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present at the Stifel Healthcare Conference

2 months ago - Business Wire

Immunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail ...

EXTON, Pa.--(BUSINESS WIRE)--Immunome Submits for Publication Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis

2 months ago - Business Wire

Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer R...

EXTON, Pa.--(BUSINESS WIRE)--Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at AACR NCI-EORTC Conference on Cancer Therapeutics

3 months ago - Business Wire

Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research N...

EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present Preclinical Data on Anti IL-38 at AACR's NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

3 months ago - Business Wire

Immunome to Present at the Cantor Global Healthcare Conference

EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present at the Cantor Global Healthcare Conference

3 months ago - Business Wire

Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

4 months ago - Business Wire

Immunome's COVID-19 Antibody Neutralizes Two Variant Strains In Animal Studies

Immunome Inc's (NASDAQ: IMNM) three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against SARS-CoV-2 Lambda (C.37) and Delta AY.1/2 (Delta Plus) variants in preclinical te...

4 months ago - Benzinga

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing

EXTON, Pa.--(BUSINESS WIRE)--Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing

4 months ago - Business Wire

Immunome Reports Second Quarter 2021 Financial Results

EXTON, Pa.--(BUSINESS WIRE)--Immunome Reports Second Quarter 2021 Financial Results

4 months ago - Business Wire

IMNM Stock: The Covid Treatment News That Has Immunome Soaring Today

IMNM stock is having a great day today. The company is preparing to move forward with expedited testing for its delta variant treatment.

5 months ago - InvestorPlace

Why Immunome's Stock Is Soaring Today

Immunome Inc (NASDAQ:IMNM) is surging Tuesday morning after the company reported the pre-clinical testing results of its antibody cocktail.  Immunome announced that its three-antibody cocktail, IMM-BCP-...

5 months ago - Benzinga

Immunome Stock Jumps As COVID-19 Antibody Shows Preclinical Neutralizing Activity Against Delta Variant

Immunome Inc (NASDAQ: IMNM) has announced that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against COVI-19 Delta variant in pre-clinical pseudovirus testing.  ...

5 months ago - Benzinga

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

EXTON, Pa.--(BUSINESS WIRE)--Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

5 months ago - Business Wire

Immunome to Present at the Ladenburg Thalmann 2021 Healthcare Conference

EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present at the Ladenburg Thalmann 2021 Healthcare Conference

6 months ago - Business Wire

Immunome Appoints Andrew Badley, M.D., to COVID-19 Advisory Board

EXTON, Pa.--(BUSINESS WIRE)--Immunome Appoints Andrew Badley, M.D., to COVID-19 Advisory Board

6 months ago - Business Wire

Immunome Appoints Franklyn G. Prendergast, M.D.

EXTON, Pa.--(BUSINESS WIRE)--Immunome Appoints Franklyn G. Prendergast, M.D., Ph.D., to Board of Directors

6 months ago - Business Wire

Immunome to Present at the Jefferies Virtual Healthcare Conference

EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present at the Jefferies Virtual Healthcare Conference

7 months ago - Business Wire

Immunome Secures Additional $4.3M Funding From DoD To Develop COVID-19 Antibody Cocktail

Immunome Inc (NASDAQ: IMNM) has secured additional funding of $4.3 million from the Department of Defense (DoD) for the development of an antibody cocktail (IMM-BCP-01) to combat SARS-CoV-2 and its vari...

7 months ago - Benzinga

Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Va...

EXTON, Pa.--(BUSINESS WIRE)--Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern

7 months ago - Business Wire